Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
| Autor: | Unchalee Permsuwan, Chaicharn Deerochanawong, Pitthaporn Chotikanokrat, Arvind Vilas Gadekar, Natapong Kosachunhanun |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Liraglutide business.industry 030503 health policy & services Health Policy Economics Econometrics and Finance (miscellaneous) Type 2 diabetes Hypoglycemia medicine.disease law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Diabetes mellitus Sitagliptin medicine Clinical endpoint 030212 general & internal medicine 0305 other medical science business Stroke medicine.drug |
| Zdroj: | ClinicoEconomics and Outcomes Research. 11:423-430 |
| ISSN: | 1178-6981 |
| DOI: | 10.2147/ceor.s201951 |
| Popis: | Aim Liraglutide, a once-daily subcutaneous glucagon-like peptide-1 (GLP-1) agonist, is approved for treatment of hyperglycemia in patients with type 2 diabetes mellitus (T2DM). For patients with established cardiovascular diseases, liraglutide has also been shown to reduce major cardiovascular events. However, its cost is relatively higher than other oral antidiabetic drugs. This study aims to compare the costs and benefits of liraglutide vs sitagliptin, in treating T2DM in Thailand. Methods This study consists of two parts. In part 1, the cost of keeping T2DM under control per patient (HbA1c |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|